{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:48:05Z","timestamp":1778780885021,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Inc.","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The recommended starting dose of eribulin in patients with hepatic impairment is based on the Child-Pugh score, largely informed by a pharmacokinetic study of 18 patients. In the pivotal studies of eribulin in metastatic breast cancer (Study 301 and Study 305 [EMBRACE]), entry criteria and dose modifications were based on liver-function test (LFT) results rather than Child-Pugh score. In populations such as patients with metastatic breast cancer, in which metastatic infiltration is the predominant cause of hepatic impairment, using Child-Pugh score may be problematic; in clinical practice, it has been more common for oncologists to make dosing decisions based on LFTs. To address this, the effects of abnormal baseline LFT results on eribulin efficacy and safety were investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this pooled post hoc analysis, 1062 patients who were randomized to receive eribulin in Studies 301 and 305 were divided into 4 groups: (A) no elevated LFT results (no liver impairment); (B) increased levels of aspartate aminotransferase and\/or alanine aminotransferase; (C) decreased albumin and\/or increased levels of aspartate aminotransferase and\/or alanine aminotransferase but not increased bilirubin; and (D) increased bilirubin. Patients were subcategorized by presence of liver metastasis. Drug exposure, dose intensity, and treatment-emergent adverse events (TEAEs) were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eribulin mesylate mean dosage was 0.82 (group A)\u20130.65\u2009mg\/m<jats:sup>2<\/jats:sup>\/week (group D). Group D had shorter treatment, more dose reductions\/delays, more TEAEs leading to dose modifications, and numerically lower objective response rates and clinical benefit rates versus groups A\u2013C. TEAE rates leading to dose modification were similar between group D (45.5%) and groups A\u2013C (range, 43.5\u201354.9%) in the absence of liver metastases, but higher in group D (91.3%) compared with groups A\u2013C (range, 41.7\u201354.3%) if liver metastases were present.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Mild elevations in bilirubin levels were associated with increased toxicity and a greater requirement for dose modifications. Based both on these study data and existing recommendations, we propose a novel scheme to guide initial dose selection in patients with metastatic breast cancer and hepatic impairment that is based on LFTs rather than Child-Pugh score.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13058-021-01407-w","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T19:13:08Z","timestamp":1616094788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Eribulin, Child-Pugh score, and liver-function tests: lessons from pivotal breast cancer studies 301 and 305"],"prefix":"10.1186","volume":"23","author":[{"given":"Iain R.","family":"Macpherson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaohua","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9496-2718","authenticated-orcid":false,"given":"Carlo","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"1407_CR1","first-page":"1013","volume":"61","author":"MJ Towle","year":"2001","unstructured":"Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61:1013\u201321.","journal-title":"Cancer Res"},{"key":"1407_CR2","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","volume":"4","author":"MA Jordan","year":"2005","unstructured":"Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4:1086\u201395.","journal-title":"Mol Cancer Ther"},{"key":"1407_CR3","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1021\/bi901810u","volume":"49","author":"JA Smith","year":"2010","unstructured":"Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2010;49:1331\u20137.","journal-title":"Biochemistry."},{"key":"1407_CR4","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914\u201323.","journal-title":"Lancet."},{"key":"1407_CR5","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33:594\u2013601.","journal-title":"J Clin Oncol"},{"key":"1407_CR6","unstructured":"Halaven (eribulin mesylate) injection [prescribing information]. Woodcliff Lake: Eisai Inc.; 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/201532s015lbl.pdf. Accessed 26 Feb 2021."},{"key":"1407_CR7","unstructured":"Halaven 0.44 mg\/ml solution for injection [summary of product characteristics]. Hertfordshire: Eisai Europe Limited. https:\/\/www.medicines.org.uk\/emc\/medicine\/24382\/SPC\/Halaven+0.44+mg+ml+solution+for+injection\/. Accessed 26 Feb 2021."},{"key":"1407_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1124\/dmd.111.042762","volume":"40","author":"AC Dubbelman","year":"2012","unstructured":"Dubbelman AC, Rosing H, Jansen RS, Mergui-Roelvink M, Huitema AD, Koetz B, et al. Mass balance study of [14C] eribulin in patients with advanced solid tumors. Drug Metab Dispos. 2012;40:313\u201321.","journal-title":"Drug Metab Dispos"},{"key":"1407_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00280-008-0755-1","volume":"62","author":"ZY Zhang","year":"2008","unstructured":"Zhang ZY, King BM, Pelletier RD, Wong YN. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol. 2008;62:707\u201316.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1407_CR10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00280-012-1976-x","volume":"70","author":"LA Devriese","year":"2012","unstructured":"Devriese LA, Witteveen PO, Marchetti S, Mergui-Roelvink M, Reyderman L, Wanders J, et al. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. Cancer Chemother Pharmacol. 2012;70:823\u201332.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1407_CR11","volume-title":"Liver and portal hypertension","author":"CG Child","year":"1964","unstructured":"Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, editor. Liver and portal hypertension. Philadelphia: Saunders; 1964."},{"key":"1407_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/bjs.1800600817","volume":"60","author":"RN Pugh","year":"1973","unstructured":"Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646\u20139.","journal-title":"Br J Surg"},{"key":"1407_CR13","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. 2005. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003122.pdf. Accessed 31 July 2020."},{"key":"1407_CR14","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. 2003. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm072123.pdf. Accessed 20 July 2020."},{"key":"1407_CR15","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S1470-2045(19)30145-7","volume":"20","author":"SD Krens","year":"2019","unstructured":"Krens SD, Lassche G, Jansman FGA, Desar IME, Lankheet NAG, Burger DM, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20:e200\u20137.","journal-title":"Lancet Oncol"},{"key":"1407_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","volume":"148","author":"C Twelves","year":"2014","unstructured":"Twelves C, Cortes J, Vahdat L, Olivo M, He Y, Kaufman PA, et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Res Treat. 2014;148:553\u201361.","journal-title":"Breast Cancer Res Treat"},{"key":"1407_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10637-012-9829-3","volume":"31","author":"LA Devriese","year":"2013","unstructured":"Devriese LA, Mergui-Roelvink M, Wanders J, Jenner A, Edwards G, Reyderman L, et al. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. Investig New Drugs. 2013;31:381\u20139.","journal-title":"Investig New Drugs"},{"key":"1407_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1359-6349(10)72280-1","volume":"8","author":"L Reyderman","year":"2011","unstructured":"Reyderman L, Gupta A, Pelletier RD, Wong N. Eribulin and cytochrome P450 effectors: in vitro studies and population pharmacokinetic\u2013pharmacodynamic analysis. EJC Suppl. 2011;8:181.","journal-title":"EJC Suppl"},{"key":"1407_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1365-2125.2012.04381.x","volume":"75","author":"LA Devriese","year":"2013","unstructured":"Devriese LA, Witteveen PE, Wanders J, Law K, Edwards G, Reyderman L, et al. Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. Br J Clin Pharmacol. 2013;75:507\u201315.","journal-title":"Br J Clin Pharmacol"},{"key":"1407_CR20","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/jcph.315","volume":"54","author":"O Majid","year":"2014","unstructured":"Majid O, Gupta A, Reyderman L, Olivo M, Hussein Z. Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. J Clin Pharmacol. 2014;54:1134\u201343.","journal-title":"J Clin Pharmacol"},{"key":"1407_CR21","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/cncr.28509","volume":"120","author":"BK Edwards","year":"2014","unstructured":"Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290\u2013314.","journal-title":"Cancer."},{"key":"1407_CR22","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.7150\/jca.24445","volume":"9","author":"Z Lin","year":"2018","unstructured":"Lin Z, Yan S, Zhang J, Pan Q. A nomogram for distinction and potential prediction of liver metastasis in breast cancer patients. J Cancer. 2018;9:2098\u2013106.","journal-title":"J Cancer"},{"key":"1407_CR23","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00280-011-1611-2","volume":"68","author":"J Horak","year":"2011","unstructured":"Horak J, White J, Harris AL, Verrill M, Carmichael J, Holt A, et al. The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemother Pharmacol. 2011;68:1485\u201395.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1407_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30296-7","volume":"20","author":"C Palmieri","year":"2019","unstructured":"Palmieri C, Macpherson I. Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution. Lancet Oncol. 2019;20:e289.","journal-title":"Lancet Oncol."},{"key":"1407_CR25","doi-asserted-by":"crossref","unstructured":"Patel H, Egorin MJ, Remick SC, Mulkerin D, Takimoto CH, Doroshow JH et al. Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): Implications for chemotherapy dosing [abstract]. J Clin Oncol. 2004;22(14 Suppl): Abstract 6051.","DOI":"10.1200\/jco.2004.22.14_suppl.6051"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-021-01407-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-021-01407-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-021-01407-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T19:26:30Z","timestamp":1616095590000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-021-01407-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1407"],"URL":"https:\/\/doi.org\/10.1186\/s13058-021-01407-w","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"9 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in the source studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable (no individual patient data are published in this article).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IR Macpherson has participated in advisory boards for Celldex Therapeutics, Daiichi-Sankyo, Eisai, Genomic Health, Novartis, Roche, and Pfizer.Y He is a former employee of Eisai Inc.C Palmieri has received funding from AstraZeneca, Pfizer, and Genomic Health, and has participated in advisory boards for Daiichi-Sankyo, Eisai, Genomic Health, Pfizer, Novartis, and Roche.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}